- Novo Nordisk’s pipeline plan: How the pharma giant is refocusing amid major restructuring
- The biggest biotech funding rounds in October 2025
- Rethinking protein production: Why Pichia pastoris is gaining ground in biotech
- AAVantgarde closes $141 million series B round to tackle inherited eye diseases
- Spooky science: lab-grown breakthroughs or nightmares?
- How AI Is revolutionizing synthetic biology and biomanufacturing
- Eight AI deals in 2025: Discover where industry leaders are betting big
- The 11 most advanced microbiome players aiming for the gut
- The ESMO 2025 digest: Is oncology in good shape?
- Pichia pastoris: the microbial protein expression platform you’re probably underestimating
- Deal after deal: Novartis spends billions in 2025
- PCSK9’s second act: From antibodies to gene editing
- Seven of the top biotech companies to know about in South San Francisco
- Five latest advancements in Tourette’s syndrome research
- NLS Days: How do things look for biotech in Sweden?
